Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial

Abstract

Wind Biotechnologies and has received research support from Tessa Therapeutics and Kuur Therapeutics. S.G. has patent applications in the elds of NK and T-cell and/or gene therapy for cancer. He is a consultant of Tessa Therapeutics, a DSMB member of Immatics, and has received honoraria from Tidal, Catamaran Bio, Sano , and Novartis within the last 2 years. N.A. is named inventor on patents and patent applications owned by BCM. N.A. received one-time royalties from Celgene and Cell Medica, consulted in the past for Adaptimmune, and continues to consult for Equillium (pro bono) and The Children's Cancer Hospital Egypt 57357. None of these relationships con ict with the published work. The remaining authors declare no competing nancial interests.